Pediatric Formulation Study

Registry ID
EUCTR2016-004728-48
Source registry
EUCTR
Phase
PHASE1
Sponsor
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.
Last update
2026-08-16

Conditions

Summary

To evaluate the comparative bioavailability of a single-dose of the investigational oral pediatric minitablet formulation of MK-1439, 0.8 mg [100 mg total dose] compared to the adult formulation of MK-1439 tablets, 100 mg in healthy adult male and female subjects under fasted conditions.

View on source registry